cohort study in Botswana. Methods: From February 2021 to July 2022, baseline HPV self-sampling was offered to women with and without HIV. Those HPV+ underwent biopsy for histopathological diagnosis. Using women without HIV as reference, risk ratios were calculated for HPV, cervical intraepithelial neoplasia (CIN) 2 or worse (CIN2+), and CIN3+, stratified by ART duration and CD4+ cell counts. Results: Of 3000 women enrolled, 2953(98.4%) underwent HPV testing, which was positive in 823(55.7%) WWH and in 654(44.3%) women without HIV. Histopathology was available for analysis in 1291(87.4%) women (709 WWH, 582 women without HIV). Over 99% of WWH had an undetectable HIV viral load and 94.4% were on a dolutegravir-based ART regimen. WWH had a higher risk of HPV [risk ratio 1.27, 95% confidence interval (95% CI): 1.18–1.37], CIN2+ (risk ratio 1.52, 95% CI: 1.16–1.98), and CIN3+ (risk ratio 1.75, 95% CI: 1.25–2.45) compared to women without HIV. There was attenuation of risk for CIN2+ with hig

ween 2021 and 2022, examining psychosocial, sexual and reproductive health in people with HIV (PWH), and compared to data from people without HIV (PWOH) in the nationally representative Project SEXUS cohort study. Health outcomes were assessed using validated patient-reported outcome measures, with sex-stratified logistic regression models adjusting for sociodemographic and other confounding factors. Results: The study included 322 men and 67 women with HIV and 15 548 men and 13 926 women without HIV. PWH were more likely to report being single and having non-Danish parentage. HIV was associated with higher odds of liver disease in both men and women, cardiovascular and lung diseases in men, and osteoporosis and hypertension in women. Compared with PWOH, men with HIV more often reported depressive symptoms or a history of treatment for anxiety, while women with HIV more often reported loneliness, suicidal thoughts and domestic abuse. Sexually, PWH more often reported reduced sexual des

agnoses nationally and by region (South, non-South), race/ethnicity (White, Hispanic/Latino, Black/African American), and transmission type (Injection-Drug Use, Male-to-Male Sexual Contact (MMSC), and Heterosexual Contact (HSC)). We employed weighted (W) and unweighted (UW) n-sub-epidemic ensemble models, calibrated using 12 years of historical data (2008–2019), and forecasted trends for 2020–2030. We compared results to identify persistent, concerning trends across models. Results: We projected substantial decreases in incident HIV diagnoses nationally (W: 27.9%, UW: 21.9%), and in the South (W:18.0%, UW: 9.2%) and non-South (W: 21.2%, UW: 19.5%) from 2019 to 2030. However, concerning nondecreasing trends were observed nationally in key sub-populations during this period: Hispanic/Latino persons (W: 1.4%, UW: 2.6%), Hispanic/Latino MMSC (W: 9.0%, UW: 9.9%), people who inject drugs (PWID) (W: 25.6%, UW: 9.2%), and White PWID (W: 3.5%, UW: 44.9%). The rising trends among Hispanic/Latino